To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study aims to evaluate if blood levels of desipramine change whilst being dosed at the same time with daily mirabegron.
Condition or disease
Pharmacokinetics of MirabegronHealthy Subjects
Drug: mirabegronDrug: desipramine
This is an open-label, one-sequence crossover design study to evaluate the drug-drug interaction between mirabegron and desipramine. The effect of mirabegron on the plasma concentration of desipramine will be evaluated after 13 day repeated administration. The recovery of CYP2D6 activity is also being explored by comparing the pharmacokinetic profiles of desipramine after a 2 week wash-out period.
Pharmacokinetics of desipramine assessed by plasma concentration while at steady state levels of mirabegron [ Time Frame: Pre-dose until 72 hours after dosing ]
Secondary Outcome Measures :
Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events [ Time Frame: Baseline until End of Study Visit (7 to 14 days after last dose) ]
Pharmacokinetics of desipramine assessed by plasma concentration after wash-out of mirabegron [ Time Frame: Pre-dose until 72 hours after wash-out ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Body Mass Index between 18.5 and 30.0 kg/m2 inclusive
Subject is genotyped and phenotyped as an extensive metabolizer for CYP2D6
Known or suspected hypersensitivity to YM178 or any of the components of the formulation used
Known or suspected hypersensitivity to desipramine or any of the components of the formulation used
Pregnant or breast feeding within 6 months before screening assessment
Any clinical history of major depressive disorder, cardiovascular disease, urinary retention, glaucoma, thyroid disease and/or seizure disorder
Any of the liver function tests (i.e. Alanine Aminotransferase (ALT), Asparate Aminotransferase (AST) and Alkaline phosphatase) above the upper limit of normal at repeated measurements
Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever)
Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests
Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as follows: pulse rate <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse rate will be measured automatically)
A marked baseline prolongation of QT/QTc interval after repeated measurements of >450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)